VC Round-Up: Microbiome Focused Lodo, T-Cell Firm Tmunity, And More
This article was originally published in Scrip
You may also be interested in...
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.